Tharimmune (THAR) director receives 5,000 stock options at $3.075
Tharimmune (THAR) reported a director stock option grant.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Tharimmune (THAR) reported a director stock option grant. On 11/03/2025, a stock option for 5,000 shares was acquired at an exercise price of $3.075. The option is exercisable on 11/03/2025 and expires on 11/03/2035.
Following the transaction, 55,000 derivative securities were beneficially owned, held directly. The grant price of the derivative security was listed as $0.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 5,000 | $0.00 | $0.00 |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Tharimmune (THAR) disclose in this Form 4?
What is the exercise price of the new Tharimmune (THAR) options?
When do the Tharimmune (THAR) options become exercisable and when do they expire?
How many derivative securities are owned after the transaction for THAR?
What was the price of the derivative security granted in the THAR filing?
What is the ownership form of the reported THAR securities?
What role does the reporting person have at Tharimmune (THAR)?
AI-generated analysis. How Rhea-AI works. Not financial advice.